M

Marker Therapeutics

D
MRKR
USD
0.51
(13.9344%)
Market Closed
139.000
Volume
-3.2
EPS
-
Div Yield
-3.626087
P/E
37,207,638.15
Market Cap
Today
3.2178%
1 Week
4.774%
1 Month
56.180%
6 Months
1.460%
12 Months
32.803%
Year To Date
-22.921%
All Time
0%

Title:
Marker Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Do you need help or have a question?